Clinical Trials Logo

AML clinical trials

View clinical trials related to AML.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT05467202 Not yet recruiting - AML Clinical Trials

Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

This is an open label, phase I study to assess the safety and efficacy of CLL1 CAR-T in patients with relapsed and refractory acute myeloid leukemia

NCT ID: NCT05463640 Not yet recruiting - AML Clinical Trials

Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML

Start date: August 2, 2022
Phase: Phase 1
Study type: Interventional

This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT04766840 Not yet recruiting - AML Clinical Trials

Donor-derived CAR-T Cells in the Treatment of AML Patients

Start date: March 1, 2021
Phase: Phase 1
Study type: Interventional

This is a clinical study to evaluate the safety and efficacy of donor-derived CAR-T cells in the treatment of patients with relapsed or refractory acute myeloid leukemia in China.

NCT ID: NCT04599452 Not yet recruiting - Elderly Clinical Trials

NK Cell Therapy Recurrent/Refractory Elderly AML

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.